Patient-Specific Induced Pluripotent Stem Cells for Disease Modeling and Phenotypic Drug Discovery

Journal of Medicinal Chemistry

Volumn 59, Issue 1, 2016, Pages 2-15

  Tang, Shibing ^a   Xie, Min ^a   Cao, Nan ^a   Ding, Sheng ^a  

^a GLADSTONE INSTITUTES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BARTH SYNDROME; BONE DISEASE; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CONGESTIVE CARDIOMYOPATHY; DIABETIC CARDIOMYOPATHY; DISEASES; DYSAUTONOMIA; HEMATOLOGIC DISEASE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LIVER DISEASE; LONG QT SYNDROME; MACHADO JOSEPH DISEASE; PARKINSON DISEASE; PHENOTYPE; PHENOTYPIC DRUG DISCOVERY; PLURIPOTENT STEM CELL; RETT SYNDROME; SCHIZOPHRENIA; SPINAL MUSCULAR ATROPHY; ANIMAL; BIOLOGICAL MODEL; DRUG DEVELOPMENT; INDUCED PLURIPOTENT STEM CELL; PERSONALIZED MEDICINE; PROCEDURES; STEM CELL TRANSPLANTATION;

ANIMALS; DRUG DISCOVERY; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MODELS, BIOLOGICAL; PHENOTYPE; PRECISION MEDICINE; STEM CELL TRANSPLANTATION;

EID: 84955291040     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00789     Document Type: Article

References (113)

1. Anighoro, A.; Bajorath, J.; Rastelli, G. Polypharmacology: challenges and opportunities in drug discovery J. Med. Chem. 2014, 57, 7874-7887 10.1021/jm5006463
2. Swinney, D. C.; Anthony, J. How were new medicines discovered? Nat. Rev. Drug Discovery 2011, 10, 507-519 10.1038/nrd3480
3. Wilding, J. L.; Bodmer, W. F. Cancer cell lines for drug discovery and development Cancer Res. 2014, 74, 2377-2384 10.1158/0008-5472.CAN-13-2971
4. Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors Cell 2007, 131, 861-872 10.1016/j.cell.2007.11.019
5. Yu, J.; Vodyanik, M. A.; Smuga-Otto, K.; Antosiewicz-Bourget, J.; Frane, J. L.; Tian, S.; Nie, J.; Jonsdottir, G. A.; Ruotti, V.; Stewart, R.; Slukvin, I. I.; Thomson, J. A. Induced pluripotent stem cell lines derived from human somatic cells Science 2007, 318, 1917-1920 10.1126/science.1151526
6. González, F.; Boué, S.; Izpisúa Belmonte, J. C. Methods for making induced pluripotent stem cells: reprogramming à la carte Nat. Rev. Genet. 2011, 12, 231-242 10.1038/nrg2937
7. Kim, D.-S.; Ross, P. J.; Zaslavsky, K.; Ellis, J. Optimizing neuronal differentiation from induced pluripotent stem cells to model ASD Front. Cell. Neurosci. 2014, 8, 109 10.3389/fncel.2014.00109
8. Lian, X.; Zhang, J.; Azarin, S. M.; Zhu, K.; Hazeltine, L. B.; Bao, X.; Hsiao, C.; Kamp, T. J.; Palecek, S. P. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions Nat. Protoc. 2013, 8, 162-175 10.1038/nprot.2012.150
9. Ma, X.; Duan, Y.; Tschudy-Seney, B.; Roll, G.; Behbahan, I. S.; Ahuja, T. P.; Tolstikov, V.; Wang, C.; McGee, J.; Khoobyari, S.; Nolta, J. A.; Willenbring, H.; Zern, M. A. Highly efficient differentiation of functional hepatocytes from human induced pluripotent stem cells Stem Cells Transl. Med. 2013, 2, 409-419 10.5966/sctm.2012-0160
10. Diekman, B. O.; Christoforou, N.; Willard, V. P.; Sun, H.; Sanchez-Adams, J.; Leong, K. W.; Guilak, F. Cartilage tissue engineering using differentiated and purified induced pluripotent stem cells Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 19172-19177 10.1073/pnas.1210422109
11. Merkle, F. T.; Eggan, K. Modeling human disease with pluripotent stem cells: from genome association to function Cell Stem Cell 2013, 12, 656-668 10.1016/j.stem.2013.05.016
12. Sterneckert, J. L.; Reinhardt, P.; Schöler, H. R. Investigating human disease using stem cell models Nat. Rev. Genet. 2014, 15, 625-639 10.1038/nrg3764
13. Zeng, X.; Hunsberger, J. G.; Simeonov, A.; Malik, N.; Pei, Y.; Rao, M. Concise review: modeling central nervous system diseases using induced pluripotent stem cells Stem Cells Transl. Med. 2014, 3, 1418-1428 10.5966/sctm.2014-0102
14. Qiang, L.; Fujita, R.; Abeliovich, A. Remodeling neurodegeneration: somatic cell reprogramming-based models of adult neurological disorders Neuron 2013, 78, 957-969 10.1016/j.neuron.2013.06.002
15. Ross, C. A.; Akimov, S. S. Human-induced pluripotent stem cells: potential for neurodegenerative diseases Hum. Mol. Genet. 2014, 23, R17-R26 10.1093/hmg/ddu204
16. Anderson, S. L.; Coli, R.; Daly, I. W.; Kichula, E. A.; Rork, M. J.; Volpi, S. A.; Ekstein, J.; Rubin, B. Y. Familial Dysautonomia is caused by mutations of the IKAP gene Am. J. Hum. Genet. 2001, 68, 753-758 10.1086/318808
17. Lee, G.; Papapetrou, E. P.; Kim, H.; Chambers, S. M.; Tomishima, M. J.; Fasano, C. A.; Ganat, Y. M.; Menon, J.; Shimizu, F.; Viale, A.; Tabar, V.; Sadelain, M.; Studer, L. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs Nature 2009, 461, 402-406 10.1038/nature08320
18. Lee, G.; Ramirez, C. N.; Kim, H.; Zeltner, N.; Liu, B.; Radu, C.; Bhinder, B.; Kim, Y. J.; Choi, I. Y.; Mukherjee-Clavin, B.; Djaballah, H.; Studer, L. Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression Nat. Biotechnol. 2012, 30, 1244-1248 10.1038/nbt.2435
19. Kolb, S. J.; Kissel, J. T. Spinal muscular atrophy: a timely review Arch. Neurol. 2011, 68, 979-984 10.1001/archneurol.2011.74
20. Ebert, A. D.; Yu, J.; Rose, F. F., Jr.; Mattis, V. B.; Lorson, C. L.; Thomson, J. A.; Svendsen, C. N. Induced pluripotent stem cells from a spinal muscular atrophy patient Nature 2009, 457, 277-280 10.1038/nature07677
21. Amir, R. E.; Van den Veyver, I. B.; Wan, M.; Tran, C. Q.; Francke, U.; Zoghbi, H. Y. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2 Nat. Genet. 1999, 23, 185-188 10.1038/13810
22. Chao, H. T.; Zoghbi, H. Y.; Rosenmund, C. MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number Neuron 2007, 56, 58-65 10.1016/j.neuron.2007.08.018
23. Marchetto, M. C.; Carromeu, C.; Acab, A.; Yu, D.; Yeo, G. W.; Mu, Y.; Chen, G.; Gage, F. H.; Muotri, A. R. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells Cell 2010, 143, 527-539 10.1016/j.cell.2010.10.016
24. Koch, P.; Breuer, P.; Peitz, M.; Jungverdorben, J.; Kesavan, J.; Poppe, D.; Doerr, J.; Ladewig, J.; Mertens, J.; Tüting, T.; Hoffmann, P.; Klockgether, T.; Evert, B. O.; Wüllner, U.; Brüstle, O. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease Nature 2011, 480, 543-546 10.1038/nature10671
25. Camp, N. J.; Neuhausen, S. L.; Tiobech, J.; Polloi, A.; Coon, H.; Myles-Worsley, M. Genomewide multipoint linkage analysis of seven extended Palauan pedigrees with schizophrenia, by a Markov-chain Monte Carlo method Am. J. Hum. Genet. 2001, 69, 1278-1289 10.1086/324590
26. Miyamoto, S.; Miyake, N.; Jarskog, L. F.; Fleischhacker, W. W.; Lieberman, J. A. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents Mol. Psychiatry 2012, 17, 1206-1227 10.1038/mp.2012.47
27. Karlsgodt, K. H.; Sun, D.; Jimenez, A. M.; Lutkenhoff, E. S.; Willhite, R.; Van Erp, T. G.; Cannon, T. D. Developmental disruptions in neural connectivity in the pathophysiology of schizophrenia Dev. Psychopathol. 2008, 20, 1297-1327 10.1017/S095457940800062X
28. Brennand, K. J.; Simone, A.; Jou, J.; Gelboin-Burkhart, C.; Tran, N.; Sangar, S.; Li, Y.; Mu, Y.; Chen, G.; Yu, D.; McCarthy, S.; Sebat, J.; Gage, F. H. Modelling schizophrenia using human induced pluripotent stem cells Nature 2011, 473, 221-225 10.1038/nature09915
29. Rodriguez-Murillo, L.; Gogos, J. A.; Karayiorgou, M. The genetic architecture of schizophrenia: new mutations and emerging paradigms Annu. Rev. Med. 2012, 63, 63-80 10.1146/annurev-med-072010-091100
30. Robberecht, W.; Philips, T. The changing scene of amyotrophic lateral sclerosis Nat. Rev. Neurosci. 2013, 14, 248-264 10.1038/nrn3430
31. Guo, W.; Chen, Y.; Zhou, X.; Kar, A.; Ray, P.; Chen, X.; Rao, E. J.; Yang, M.; Ye, H.; Zhu, L.; Liu, J.; Xu, M.; Yang, Y.; Wang, C.; Zhang, D.; Bigio, E. H.; Mesulam, M.; Shen, Y.; Xu, Q.; Fushimi, K.; Wu, J. Y. An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity Nat. Struct. Mol. Biol. 2011, 18, 822-830 10.1038/nsmb.2053
32. Egawa, N.; Kitaoka, S.; Tsukita, K.; Naitoh, M.; Takahashi, K.; Yamamoto, T.; Adachi, F.; Kondo, T.; Okita, K.; Asaka, I.; Aoi, T.; Watanabe, A.; Yamada, Y.; Morizane, A.; Takahashi, J.; Ayaki, T.; Ito, H.; Yoshikawa, K.; Yamawaki, S.; Suzuki, S.; Watanabe, D.; Hioki, H.; Kaneko, T.; Makioka, K.; Okamoto, K.; Takuma, H.; Tamaoka, A.; Hasegawa, K.; Nonaka, T.; Hasegawa, M.; Kawata, A.; Yoshida, M.; Nakahata, T.; Takahashi, R.; Marchetto, M. C.; Gage, F. H.; Yamanaka, S.; Inoue, H. Drug screening for ALS using patient-specific induced pluripotent stem cells Sci. Transl. Med. 2012, 4, 145ra104 10.1126/scitranslmed.3004052
33. Strong, M. J.; Kesavapany, S.; Pant, H. C. The pathobiology of amyotrophic lateral sclerosis: a proteinopathy? J. Neuropathol. Exp. Neurol. 2005, 64, 649-664 10.1097/01.jnen.0000173889.71434.ea
34. Yang, Y. M.; Gupta, S. K.; Kim, K. J.; Powers, B. E.; Cerqueira, A.; Wainger, B. J.; Ngo, H. D.; Rosowski, K. A.; Schein, P. A.; Ackeifi, C. A.; Arvanites, A. C.; Davidow, L. S.; Woolf, C. J.; Rubin, L. L. A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS Cell Stem Cell 2013, 12, 713-726 10.1016/j.stem.2013.04.003
35. Burkhardt, M. F.; Martinez, F. J.; Wright, S.; Ramos, C.; Volfson, D.; Mason, M.; Garnes, J.; Dang, V.; Lievers, J.; Shoukat-Mumtaz, U.; Martinez, R.; Gai, H.; Blake, R.; Vaisberg, E.; Grskovic, M.; Johnson, C.; Irion, S.; Bright, J.; Cooper, B.; Nguyen, L.; Griswold-Prenner, I.; Javaherian, A. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells Mol. Cell. Neurosci. 2013, 56, 355-364 10.1016/j.mcn.2013.07.007
36. Pasinelli, P.; Brown, R. H. Molecular biology of amyotrophic lateral sclerosis: insights from genetics Nat. Rev. Neurosci. 2006, 7, 710-723 10.1038/nrn1971
37. Cleveland, D. W.; Rothstein, J. D. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS Nat. Rev. Neurosci. 2001, 2, 806-819 10.1038/35097565
38. Wainger, B. J.; Kiskinis, E.; Mellin, C.; Wiskow, O.; Han, S. S.; Sandoe, J.; Perez, N. P.; Williams, L. A.; Lee, S.; Boulting, G.; Berry, J. D.; Brown, R. H., Jr.; Cudkowicz, M. E.; Bean, B. P.; Eggan, K.; Woolf, C. J. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons Cell Rep. 2014, 7, 1-11 10.1016/j.celrep.2014.03.019
39. de Lau, L. M.; Breteler, M. M. Epidemiology of Parkinsons disease Lancet Neurol. 2006, 5, 525-535 10.1016/S1474-4422(06)70471-9
40. Connolly, B. S.; Lang, A. E. Pharmacological treatment of Parkinson disease: a review J. Am. Med. Assoc. 2014, 311, 1670-1683 10.1001/jama.2014.3654
41. Hall, H.; Reyes, S.; Landeck, N.; Bye, C.; Leanza, G.; Double, K.; Thompson, L.; Halliday, G.; Kirik, D. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinsons disease Brain 2014, 137, 2493-2508 10.1093/brain/awu193
42. Exner, N.; Lutz, A. K.; Haass, C.; Winklhofer, K. F. Mitochondrial dysfunction in Parkinsons disease: molecular mechanisms and pathophysiological consequences EMBO J. 2012, 31, 3038-3062 10.1038/emboj.2012.170
43. Henchcliffe, C.; Beal, M. F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis Nat. Clin. Pract. Neurol. 2008, 4, 600-609 10.1038/ncpneuro0924
44. Shulman, J. M.; De Jager, P. L.; Feany, M. B. Parkinsons disease: genetics and pathogenesis Annu. Rev. Pathol.: Mech. Dis. 2011, 6, 193-222 10.1146/annurev-pathol-011110-130242
45. Cooper, O.; Seo, H.; Andrabi, S.; Guardia-Laguarta, C.; Graziotto, J.; Sundberg, M.; McLean, J. R.; Carrillo-Reid, L.; Xie, Z.; Osborn, T.; Hargus, G.; Deleidi, M.; Lawson, T.; Bogetofte, H.; Perez-Torres, E.; Clark, L.; Moskowitz, C.; Mazzulli, J.; Chen, L.; Volpicelli-Daley, L.; Romero, N.; Jiang, H.; Uitti, R. J.; Huang, Z.; Opala, G.; Scarffe, L. A.; Dawson, V. L.; Klein, C.; Feng, J.; Ross, O. A.; Trojanowski, J. Q.; Lee, V. M.; Marder, K.; Surmeier, D. J.; Wszolek, Z. K.; Przedborski, S.; Krainc, D.; Dawson, T. M.; Isacson, O. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinsons disease Sci. Transl. Med. 2012, 4, 141ra90 10.1126/scitranslmed.3003985
46. Reinhardt, P.; Schmid, B.; Burbulla, L. F.; Schöndorf, D. C.; Wagner, L.; Glatza, M.; Höing, S.; Hargus, G.; Heck, S. A.; Dhingra, A.; Wu, G.; Müller, S.; Brockmann, K.; Kluba, T.; Maisel, M.; Krüger, R.; Berg, D.; Tsytsyura, Y.; Thiel, C. S.; Psathaki, O. E.; Klingauf, J.; Kuhlmann, T.; Klewin, M.; Müller, H.; Gasser, T.; Schöler, H. R.; Sterneckert, J. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression Cell Stem Cell 2013, 12, 354-367 10.1016/j.stem.2013.01.008
47. Irwin, D. J.; Lee, V. M. Y.; Trojanowski, J. Q. Parkinsons disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies Nat. Rev. Neurosci. 2013, 14, 626-636 10.1038/nrn3549
48. Wilkaniec, A.; Strosznajder, J. B.; Adamczyk, A. Toxicity of extracellular secreted α-synuclein: Its role in nitrosative stress and neurodegeneration Neurochem. Int. 2013, 62, 776-783 10.1016/j.neuint.2013.02.004
49. Chung, C. Y.; Khurana, V.; Auluck, P. K.; Tardiff, D. F.; Mazzulli, J. R.; Soldner, F.; Baru, V.; Lou, Y.; Freyzon, Y.; Cho, S.; Mungenast, A. E.; Muffat, J.; Mitalipova, M.; Pluth, M. D.; Jui, N. T.; Schüle, B.; Lippard, S. J.; Tsai, L. H.; Krainc, D.; Buchwald, S. L.; Jaenisch, R.; Lindquist, S. Identification and rescue of α-synuclein toxicity in parkinson patient-derived neurons Science 2013, 342, 983-987 10.1126/science.1245296
50. Tardiff, D. F.; Jui, N. T.; Khurana, V.; Tambe, M. A.; Thompson, M. L.; Chung, C. Y.; Kamadurai, H. B.; Kim, H. T.; Lancaster, A. K.; Caldwell, K. A.; Caldwell, G. A.; Rochet, J. C.; Buchwald, S. L.; Lindquist, S. Yeast reveal a «druggable» Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons Science 2013, 342, 979-983 10.1126/science.1245321
51. Chiang, K.; Koo, E. H. Emerging therapeutics for Alzheimers disease Annu. Rev. Pharmacol. Toxicol. 2014, 54, 381-405 10.1146/annurev-pharmtox-011613-135932
52. Huang, Y.; Mucke, L. Alzheimer mechanisms and therapeutic strategies Cell 2012, 148, 1204-1222 10.1016/j.cell.2012.02.040
53. Bertram, L.; Lill, C. M.; Tanzi, R. E. The genetics of Alzheimer disease: back to the future Neuron 2010, 68, 270-281 10.1016/j.neuron.2010.10.013
54. Serrano-Pozo, A.; Frosch, M. P.; Masliah, E.; Hyman, B. T. Neuropathological alterations in Alzheimer disease Cold Spring Harbor Perspect. Med. 2011, 1, a006189 10.1101/cshperspect.a006189
55. Tanzi, R. E.; Bertram, L. Twenty years of the Alzheimers disease amyloid hypothesis: a genetic perspective Cell 2005, 120, 545-555 10.1016/j.cell.2005.02.008
56. Yagi, T.; Ito, D.; Okada, Y.; Akamatsu, W.; Nihei, Y.; Yoshizaki, T.; Yamanaka, S.; Okano, H.; Suzuki, N. Modeling familial Alzheimers disease with induced pluripotent stem cells Hum. Mol. Genet. 2011, 20, 4530-4539 10.1093/hmg/ddr394
57. Hampel, H.; Blennow, K.; Shaw, L. M.; Hoessler, Y. C.; Zetterberg, H.; Trojanowski, J. Q. Total and phosphorylated tau protein as biological markers of Alzheimers disease Exp. Gerontol. 2010, 45, 30-40 10.1016/j.exger.2009.10.010
58. Israel, M. A.; Yuan, S. H.; Bardy, C.; Reyna, S. M.; Mu, Y.; Herrera, C.; Hefferan, M. P.; Van Gorp, S.; Nazor, K. L.; Boscolo, F. S.; Carson, C. T.; Laurent, L. C.; Marsala, M.; Gage, F. H.; Remes, A. M.; Koo, E. H.; Goldstein, L. S. Probing sporadic and familial Alzheimers disease using induced pluripotent stem cells Nature 2012, 482, 216-220 10.1038/nature10821
59. Kondo, T.; Asai, M.; Tsukita, K.; Kutoku, Y.; Ohsawa, Y.; Sunada, Y.; Imamura, K.; Egawa, N.; Yahata, N.; Okita, K.; Takahashi, K.; Asaka, I.; Aoi, T.; Watanabe, A.; Watanabe, K.; Kadoya, C.; Nakano, R.; Watanabe, D.; Maruyama, K.; Hori, O.; Hibino, S.; Choshi, T.; Nakahata, T.; Hioki, H.; Kaneko, T.; Naitoh, M.; Yoshikawa, K.; Yamawaki, S.; Suzuki, S.; Hata, R.; Ueno, S.; Seki, T.; Kobayashi, K.; Toda, T.; Murakami, K.; Irie, K.; Klein, W. L.; Mori, H.; Asada, T.; Takahashi, R.; Iwata, N.; Yamanaka, S.; Inoue, H. Modeling Alzheimers disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness Cell Stem Cell 2013, 12, 487-496 10.1016/j.stem.2013.01.009
60. Mummery, C. L.; Zhang, J.; Ng, E. S.; Elliott, D. A.; Elefanty, A. G.; Kamp, T. J. Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview Circ. Res. 2012, 111, 344-358 10.1161/CIRCRESAHA.110.227512
61. Matsa, E.; Burridge, P. W.; Wu, J. C. Human stem cells for modeling heart disease and for drug discovery Sci. Transl. Med. 2014, 6, 239ps6 10.1126/scitranslmed.3008921
62. Carvajal-Vergara, X.; Sevilla, A.; DSouza, S. L.; Ang, Y. S.; Schaniel, C.; Lee, D. F.; Yang, L.; Kaplan, A. D.; Adler, E. D.; Rozov, R.; Ge, Y.; Cohen, N.; Edelmann, L. J.; Chang, B.; Waghray, A.; Su, J.; Pardo, S.; Lichtenbelt, K. D.; Tartaglia, M.; Gelb, B. D.; Lemischka, I. R. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome Nature 2010, 465, 808-812 10.1038/nature09005
63. Mercola, M.; Colas, A.; Willems, E. Induced pluripotent stem cells in cardiovascular drug discovery Circ. Res. 2013, 112, 534-548 10.1161/CIRCRESAHA.111.250266
64. Sinnecker, D.; Laugwitz, K. L.; Moretti, A. Induced pluripotent stem cell-derived cardiomyocytes for drug development and toxicity testing Pharmacol. Ther. 2014, 143, 246-252 10.1016/j.pharmthera.2014.03.004
65. Mordwinkin, N. M.; Burridge, P. W.; Wu, J. C. A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards J. Cardiovasc. Transl. Res. 2013, 6, 22-30 10.1007/s12265-012-9423-2
66. Goldenberg, I.; Moss, A. J. Long QT syndrome J. Am. Coll. Cardiol. 2008, 51, 2291-2300 10.1016/j.jacc.2008.02.068
67. Moss, A. J.; Kass, R. S. Long QT syndrome: from channels to cardiac arrhythmias J. Clin. Invest. 2005, 115, 2018-2024 10.1172/JCI25537
68. Moretti, A.; Bellin, M.; Welling, A.; Jung, C. B.; Lam, J. T.; Bott-Flügel, L.; Dorn, T.; Goedel, A.; Höhnke, C.; Hofmann, F.; Seyfarth, M.; Sinnecker, D.; Schömig, A.; Laugwitz, K. L. Patient-specific induced pluripotent stem-cell models for long-QT syndrome N. Engl. J. Med. 2010, 363, 1397-1409 10.1056/NEJMoa0908679
69. Matsa, E.; Rajamohan, D.; Dick, E.; Young, L.; Mellor, I.; Staniforth, A.; Denning, C. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation Eur. Heart J. 2011, 32, 952-962 10.1093/eurheartj/ehr073
70. Itzhaki, I.; Maizels, L.; Huber, I.; Zwi-Dantsis, L.; Caspi, O.; Winterstern, A.; Feldman, O.; Gepstein, A.; Arbel, G.; Hammerman, H.; Boulos, M.; Gepstein, L. Modelling the long QT syndrome with induced pluripotent stem cells Nature 2011, 471, 225-229 10.1038/nature09747
71. Terrenoire, C.; Wang, K.; Tung, K. W. C.; Chung, W. K.; Pass, R. H.; Lu, J. T.; Jean, J. C.; Omari, A.; Sampson, K. J.; Kotton, D. N.; Keller, G.; Kass, R. S. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics J. Gen. Physiol. 2013, 141, 61-72 10.1085/jgp.201210899
72. Ma, D.; Wei, H.; Zhao, Y.; Lu, J.; Li, G.; Sahib, N. B. E.; Tan, T. H.; Wong, K. Y.; Shim, W.; Wong, P.; Cook, S. A.; Liew, R. Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells Int. J. Cardiol. 2013, 168, 5277-5286 10.1016/j.ijcard.2013.08.015
73. Splawski, I.; Timothy, K. W.; Sharpe, L. M.; Decher, N.; Kumar, P.; Bloise, R.; Napolitano, C.; Schwartz, P. J.; Joseph, R. M.; Condouris, K.; Tager-Flusberg, H.; Priori, S. G.; Sanguinetti, M. C.; Keating, M. T. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism Cell 2004, 119, 19-31 10.1016/j.cell.2004.09.011
74. Yazawa, M.; Hsueh, B.; Jia, X.; Pasca, A. M.; Bernstein, J. A.; Hallmayer, J.; Dolmetsch, R. E. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome Nature 2011, 471, 230-234 10.1038/nature09855
75. Jung, C. B.; Moretti, A.; Mederos y Schnitzler, M.; Iop, L.; Storch, U.; Bellin, M.; Dorn, T.; Ruppenthal, S.; Pfeiffer, S.; Goedel, A.; Dirschinger, R. J.; Seyfarth, M.; Lam, J. T.; Sinnecker, D.; Gudermann, T.; Lipp, P.; Laugwitz, K. L. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia EMBO Mol. Med. 2012, 4, 180-191 10.1002/emmm.201100194
76. Itzhaki, I.; Maizels, L.; Huber, I.; Gepstein, A.; Arbel, G.; Caspi, O.; Miller, L.; Belhassen, B.; Nof, E.; Glikson, M.; Gepstein, L. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells J. Am. Coll. Cardiol. 2012, 60, 990-1000 10.1016/j.jacc.2012.02.066
77. Maron, B. J.; Towbin, J. A.; Thiene, G.; Antzelevitch, C.; Corrado, D.; Arnett, D.; Moss, A. J.; Seidman, C. E.; Young, J. B. Contemporary definitions and classification of the cardiomyopathies. An American Heart Association scientific statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention Circulation 2006, 113, 1807-1816 10.1161/CIRCULATIONAHA.106.174287
78. Sun, N.; Yazawa, M.; Liu, J.; Han, L.; Sanchez-Freire, V.; Abilez, O. J.; Navarrete, E. G.; Hu, S.; Wang, L.; Lee, A.; Pavlovic, A.; Lin, S.; Chen, R.; Hajjar, R. J.; Snyder, M. P.; Dolmetsch, R. E.; Butte, M. J.; Ashley, E. A.; Longaker, M. T.; Robbins, R. C.; Wu, J. C. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy Sci. Transl. Med. 2012, 4, 130ra47 10.1126/scitranslmed.3003552
79. Maron, B. J.; Gardin, J. M.; Flack, J. M.; Gidding, S. S.; Kurosaki, T. T.; Bild, D. E. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults Circulation 1995, 92, 785-789 10.1161/01.CIR.92.4.785
80. Seidman, J. G.; Seidman, C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms Cell 2001, 104, 557-567 10.1016/S0092-8674(01)00242-2
81. Lan, F.; Lee, A. S.; Liang, P.; Sanchez-Freire, V.; Nguyen, P. K.; Wang, L.; Han, L.; Yen, M.; Wang, Y.; Sun, N.; Abilez, O. J.; Hu, S.; Ebert, A. D.; Navarrete, E. G.; Simmons, C. S.; Wheeler, M.; Pruitt, B.; Lewis, R.; Yamaguchi, Y.; Ashley, E. A.; Bers, D. M.; Robbins, R. C.; Longaker, M. T.; Wu, J. C. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells Cell Stem Cell 2013, 12, 101-113 10.1016/j.stem.2012.10.010
82. Clarke, S. L.; Bowron, A.; Gonzalez, I. L.; Groves, S. J.; Newbury-Ecob, R.; Clayton, N.; Martin, R. P.; Tsai-Goodman, B.; Garratt, V.; Ashworth, M.; Bowen, V. M.; McCurdy, K. R.; Damin, M. K.; Spencer, C. T.; Toth, M. J.; Kelley, R. I.; Steward, C. G. Barth syndrome Orphanet J. Rare Dis. 2013, 8, 23 10.1186/1750-1172-8-23
83. Chicco, A. J.; Sparagna, G. C. Role of cardiolipin alterations in mitochondrial dysfunction and disease Am. J. Physiol.: Cell Physiol. 2007, 292, C33-C44 10.1152/ajpcell.00243.2006
84. Wang, G.; McCain, M. L.; Yang, L.; He, A.; Pasqualini, F. S.; Agarwal, A.; Yuan, H.; Jiang, D.; Zhang, D.; Zangi, L.; Geva, J.; Roberts, A. E.; Ma, Q.; Ding, J.; Chen, J.; Wang, D. Z.; Li, K.; Wang, J.; Wanders, R. J.; Kulik, W.; Vaz, F. M.; Laflamme, M. A.; Murry, C. E.; Chien, K. R.; Kelley, R. I.; Church, G. M.; Parker, K. K.; Pu, W. T. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies Nat. Med. 2014, 20, 616-623 10.1038/nm.3545
85. Drawnel, F. M.; Boccardo, S.; Prummer, M.; Delobel, F.; Graff, A.; Weber, M.; Gérard, R.; Badi, L.; Kam-Thong, T.; Bu, L.; Jiang, X.; Hoflack, J. C.; Kiialainen, A.; Jeworutzki, E.; Aoyama, N.; Carlson, C.; Burcin, M.; Gromo, G.; Boehringer, M.; Stahlberg, H.; Hall, B. J.; Magnone, M. C.; Kolaja, K.; Chien, K. R.; Bailly, J.; Iacone, R. Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells Cell Rep. 2014, 9, 810-821 10.1016/j.celrep.2014.09.055
86. Yi, F.; Liu, G. H.; Izpisúa Belmonte, J. C. Human induced pluripotent stem cells derived hepatocytes: rising promise for disease modeling, drug development and cell therapy Protein Cell 2012, 3, 246-250 10.1007/s13238-012-2918-4
87. Ala, A.; Walker, A. P.; Ashkan, K.; Dooley, J. S.; Schilsky, M. L. Wilsons disease Lancet 2007, 369, 397-408 10.1016/S0140-6736(07)60196-2
88. Zhang, S.; Chen, S.; Li, W.; Guo, X.; Zhao, P.; Xu, J.; Chen, Y.; Pan, Q.; Liu, X.; Zychlinski, D.; Lu, H.; Tortorella, M. D.; Schambach, A.; Wang, Y.; Pei, D.; Esteban, M. A. Rescue of ATP7B function in hepatocyte-like cells from Wilsons disease induced pluripotent stem cells using gene therapy or the chaperone drug curcumin Hum. Mol. Genet. 2011, 20, 3176-3187 10.1093/hmg/ddr223
89. Choi, S. M.; Kim, Y.; Shim, J. S.; Park, J. T.; Wang, R. H.; Leach, S. D.; Liu, J. O.; Deng, C.; Ye, Z.; Jang, Y. Y. Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells Hepatology 2013, 57, 2458-2468 10.1002/hep.26237
90. Boocock, G. R.; Morrison, J. A.; Popovic, M.; Richards, N.; Ellis, L.; Durie, P. R.; Rommens, J. M. Mutations in SBDS are associated with Shwachman-Diamond syndrome Nat. Genet. 2002, 33, 97-101 10.1038/ng1062
91. Tulpule, A.; Kelley, J. M.; Lensch, M. W.; McPherson, J.; Park, I. H.; Hartung, O.; Nakamura, T.; Schlaeger, T. M.; Shimamura, A.; Daley, G. Q. Pluripotent stem cell models of shwachman-diamond syndrome reveal a common mechanism for pancreatic and hematopoietic dysfunction Cell Stem Cell 2013, 12, 727-736 10.1016/j.stem.2013.04.002
92. Liu, G.-H.; Suzuki, K.; Li, M.; Qu, J.; Montserrat, N.; Tarantino, C.; Gu, Y.; Yi, F.; Xu, X.; Zhang, W.; Ruiz, S.; Plongthongkum, N.; Zhang, K.; Masuda, S.; Nivet, E.; Tsunekawa, Y.; Soligalla, R. D.; Goebl, A.; Aizawa, E.; Kim, N. Y.; Kim, J.; Dubova, I.; Li, Y.; Ren, R.; Benner, C.; del Sol, A.; Bueren, J.; Trujillo, J. P.; Surralles, J.; Cappelli, E.; Dufour, C.; Esteban, C. R.; Izpisúa Belmonte, J. C. Modelling Fanconi anemia pathogenesis and therapeutics using integration-free patient-derived iPSCs Nat. Commun. 2014, 5, 4330 10.1038/ncomms5330
93. Moldovan, G. L.; DAndrea, A. D. How the fanconi anemia pathway guards the genome Annu. Rev. Genet. 2009, 43, 223-249 10.1146/annurev-genet-102108-134222
94. Muller, L. U.; Milsom, M. D.; Harris, C. E.; Vyas, R.; Brumme, K. M.; Parmar, K.; Moreau, L. A.; Schambach, A.; Park, I. H.; London, W. B.; Strait, K.; Schlaeger, T.; Devine, A. L.; Grassman, E.; DAndrea, A.; Daley, G. Q.; Williams, D. A. Overcoming reprogramming resistance of Fanconi anemia cells Blood 2012, 119, 5449-5457 10.1182/blood-2012-02-408674
95. Pereira, L.; Andrikopoulos, K.; Tian, J.; Lee, S. Y.; Keene, D. R.; Ono, R.; Reinhardt, D. P.; Sakai, L. Y.; Biery, N. J.; Bunton, T.; Dietz, H. C.; Ramirez, F. Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome Nat. Genet. 1997, 17, 218-222 10.1038/ng1097-218
96. Quarto, N.; Leonard, B.; Li, S.; Marchand, M.; Anderson, E.; Behr, B.; Francke, U.; Reijo-Pera, R.; Chiao, E.; Longaker, M. T. Skeletogenic phenotype of human Marfan embryonic stem cells faithfully phenocopied by patient-specific induced-pluripotent stem cells Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 215-220 10.1073/pnas.1113442109
97. Shore, E. M.; Xu, M.; Feldman, G. J.; Fenstermacher, D. A.; Cho, T. J.; Choi, I. H.; Connor, J. M.; Delai, P.; Glaser, D. L.; LeMerrer, M.; Morhart, R.; Rogers, J. G.; Smith, R.; Triffitt, J. T.; Urtizberea, J. A.; Zasloff, M.; Brown, M. A.; Kaplan, F. S. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva Nat. Genet. 2006, 38, 525-527 10.1038/ng1783
98. Matsumoto, Y.; Hayashi, Y.; Schlieve, C. R.; Ikeya, M.; Kim, H.; Nguyen, T. D.; Sami, S.; Baba, S.; Barruet, E.; Nasu, A.; Asaka, I.; Otsuka, T.; Yamanaka, S.; Conklin, B. R.; Toguchida, J.; Hsiao, E. C. Induced pluripotent stem cells from patients with human fibrodysplasia ossificans progressiva show increased mineralization and cartilage formation Orphanet J. Rare Dis. 2013, 8, 190 10.1186/1750-1172-8-190
99. Yamashita, A.; Morioka, M.; Kishi, H.; Kimura, T.; Yahara, Y.; Okada, M.; Fujita, K.; Sawai, H.; Ikegawa, S.; Tsumaki, N. Statin treatment rescues FGFR3 skeletal dysplasia phenotypes Nature 2014, 513, 507-511 10.1038/nature13775
100. Vajo, Z.; Francomano, C. A.; Wilkin, D. J. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans Endocr. Rev. 2000, 21, 23-39 10.1210/edrv.21.1.0387
101. Bayart, E.; Cohen-Haguenauer, O. Technological overview of iPS induction from human adult somatic cells Curr. Gene Ther. 2013, 13, 73-92 10.2174/1566523211313020002
102. Engle, S. J.; Puppala, D. Integrating human pluripotent stem cells into drug development Cell Stem Cell 2013, 12, 669-677 10.1016/j.stem.2013.05.011
103. Yang, X.; Pabon, L.; Murry, C. E. Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes Circ. Res. 2014, 114, 511-523 10.1161/CIRCRESAHA.114.300558
104. Burridge, P. W.; Matsa, E.; Shukla, P.; Lin, Z. C.; Churko, J. M.; Ebert, A. D.; Lan, F.; Diecke, S.; Huber, B.; Mordwinkin, N. M.; Plews, J. R.; Abilez, O. J.; Cui, B.; Gold, J. D.; Wu, J. C. Chemically defined generation of human cardiomyocytes Nat. Methods 2014, 11, 855-860 10.1038/nmeth.2999
105. Musunuru, K. Genome editing of human pluripotent stem cells to generate human cellular disease models Dis. Models & Mech. 2013, 6, 896-904 10.1242/dmm.012054
106. Vincent, F.; Loria, P.; Pregel, M.; Stanton, R.; Kitching, L.; Nocka, K.; Doyonnas, R.; Steppan, C.; Gilbert, A.; Schroeter, T.; Peakman, M. C. Developing predictive assays: The phenotypic screening «rule of 3» Sci. Transl. Med. 2015, 7, 293ps15 10.1126/scitranslmed.aab1201
107. Hynds, R. E.; Giangreco, A. Concise review: the relevance of human stem cell-derived organoid models for epithelial translational medicine Stem Cells 2013, 31, 417-422 10.1002/stem.1290
108. Mathur, A.; Loskill, P.; Shao, K.; Huebsch, N.; Hong, S.; Marcus, S. G.; Marks, N.; Mandegar, M.; Conklin, B. R.; Lee, L. P.; Healy, K. E. Human iPSC-based cardiac microphysiological system for drug screening applications Sci. Rep. 2015, 5, 8883 10.1038/srep08883
109. Lancaster, M. A.; Renner, M.; Martin, C. A.; Wenzel, D.; Bicknell, L. S.; Hurles, M. E.; Homfray, T.; Penninger, J. M.; Jackson, A. P.; Knoblich, J. A. Cerebral organoids model human brain development and microcephaly Nature 2013, 501, 373-379 10.1038/nature12517
110. Choi, S. H.; Kim, Y. H.; Hebisch, M.; Sliwinski, C.; Lee, S.; DAvanzo, C.; Chen, H.; Hooli, B.; Asselin, C.; Muffat, J.; Klee, J. B.; Zhang, C.; Wainger, B. J.; Peitz, M.; Kovacs, D. M.; Woolf, C. J.; Wagner, S. L.; Tanzi, R. E.; Kim, D. Y. A three-dimensional human neural cell culture model of Alzheimers disease Nature 2014, 515, 274-278 10.1038/nature13800
111. Matsusaki, M.; Case, C. P.; Akashi, M. Three-dimensional cell culture technique and pathophysiology Adv. Drug Delivery Rev. 2014, 74, 95-103 10.1016/j.addr.2014.01.003
112. Wagner, B. K.; Tolliday, N. J.; Clemons, P. A., Eds. Cell-Based Assays for High-Throughput Screening: Methods and Protocols; Humana Press: Totowa, NJ, 2009.
113. Harrison, C. Phenotypic screening: A more rapid route to target deconvolution Nat. Rev. Drug Discovery 2014, 13, 102-103 10.1038/nrd4243